Skip to main content

Table 3 Mixed relative treatment effects of composite adverse events and estimated glomerular filtration rate among urate lowering agents

From: Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials

eGFR; MD (95% CI)

Probenecid

-

-

-

0.52

(0.08, 3.52)

Febuxostat

-0.80

(-2.66, 1.05)

2.89

(0.69, 5.09)

0.42

(0.10, 1.73)

0.80

(0.23, 2.82)

Allopurinol

3.69

(1.31, 6.08)

0.68

(0.16, 2.84)

1.30

(0.28, 5.99)

1.63

(0.70, 3.79)

Placebo/no ULT

Adverse events; RR (95% CI)

  1. CI Confidence interval, eGFR Estimated glomerular filtration rates, MD Mean difference, RR Risk ratio, ULT Urate-lowering therapy agents
  2. Comparisons are read from left to right for both eGFR and adverse events. For example; allopurinol had higher adverse events with RR (95% CI) of 1.63 (0.70, 3.79) compared with placebo/no ULT, and higher eGFR with MD (95% CI) of 3.69 (1.31, 6.08) compared with placebo/no ULT
  3. Bold font indicates statistical significance
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us